Management of heparin in COVID-19 patients during the first phase of pandemic

Authors

  • Gianluca Sottilotta Hemophilia Centre, Thrombosis and Haemostasis Service, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Carmelo Mangano Unit of Infectious Disease, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Rosa Basile Unit of Infectious Disease, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Francesca Luise Analysis Laboratory, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Demetrio Megalizzi Hemophilia Centre, Thrombosis and Haemostasis Service, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Giovanna Maria Nicolò Clinical Pathology and Clinical Biochemistry, University of Catania, Italy
  • Vincenzo Oriana Hemophilia Centre, Thrombosis and Haemostasis Service, Grande Ospedale Metropolitano, Reggio Calabria, Italy
  • Angela Piromalli Analysis Laboratory, Grande Ospedale Metropolitano, Reggio Calabria, Italy

Abstract

The coronavirus disease (COVID-19) is associated with a significant risk of thrombotic complications.
We reported our first wave experience regarding the use of Low Molecular Weight Heparin (LMWH)
and Fondaparinux in Covid-19 patients admitted to our Hospital. The aim of our study was to evaluate
the effectiveness and safety of increased LWMH prophylaxis. 57 patients admitted to our hospital
for COVID-19, median age 65, were studied from March to May 2020. We observed one thrombotic
event and 3 bleedings. The incidence of thrombosis was 1.7%: this result is much lower than that
reported by other studies regarding patients untreated with heparin or in prophylaxis at standard
dosages. LMWH therapy has proven effective and safe in terms of thrombosis prevention and has
contributed to the favourable outcome of hospitalizations.

Downloads

Published

2020-12-12

Issue

Vol. 1 No. 2

Section

Articles